Lexeo Therapeutics Receives Breakthrough Therapy Designation for LX2006 in Friedreich Ataxia
Lexeo Therapeutic has received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for its investigational treatment LX2006.
The designation was granted based on early clinical evidence showing improvements in both cardiac and neurological outcomes in patients with Friedreich ataxia (FA).
In addition, LX2006 has been selected for inclusion in the FDA’s Chemistry, Manufacturing, and Controls (CMC) Development and Readiness Pilot (CDRP) programme.
This initiative is designed to support earlier patient access to treatments being developed on accelerated timelines, by enhancing regulatory communication related to manufacturing and development processes.
The FDA’s decision follows interim data from two ongoing trials, the SUNRISE-FA Phase 1/2 study led by Lexeo (NCT05445323) and an investigator-initiated Phase 1A trial at Weill Cornell Medicine (NCT05302271).
Seventeen participants have been treated across both studies. Results showed meaningful improvements in cardiac biomarkers and in cardiac and neurological function, along with increased frataxin expression in all patients who underwent cardiac biopsies three months after treatment.
FA is a progressive genetic condition that often leads to cardiomyopathy, the most common cause of death in people with the disease. There are currently no approved treatments targeting the cardiac symptoms specifically.
Lexeo is also running a prospective natural history study, CLARITY-FA, which will provide a concurrent external control group for its future registrational study.
The company plans to launch this pivotal trial in early 2026 and is working closely with the FDA to finalise the statistical analysis plan.
LX2006 has already received multiple FDA designations, including Regenerative Medicine Advanced Therapy (RMAT), Orphan Drug, and Fast Track status.
The recent Breakthrough Therapy designation aims to speed up the development and review process for therapies showing early signs of clinical benefit over existing options.
